<DOC>
	<DOCNO>NCT00191191</DOCNO>
	<brief_summary>To investigate efficacy safety pemetrexed second third line therapy patient non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>To Investigate Efficacy Safety Pemetrexed Second Third Line Therapy Patients With Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Clinical stage III IV Previously treat one two chemotherapeutic regimen Performance status : 02 Inability unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>